To NASDAQ OMX Copenhagen A/S
Announcement no. 20-12 / Copenhagen, November 6, 2012
The Board of Directors has decided to advance the release of Topotarget’s interim report for Q3 2012 from November 21 to November 12, 2012 for practical reasons.
In 2013, the company expects to publish financial reports on the following dates:
Interim report for Q4 2012 January 31, 2013
Annual report for 2012 March 13, 2013
Interim report for Q1 2013 May 2, 2013
Interim report for Q2 2013 August 14, 2013
Interim report for Q3 2013 November 7, 2013
The company’s next Annual General Meeting is planned for April 10, 2013.
Topotarget A/S
For further information, please contact:
Anders Vadsholt, CEO: Direct: +45 39178345; Cell: +45 28989055
Background information
About Topotarget
Topotarget (NASDAQ OMX: TOPO) is an international biopharmaceutical company headquartered in Copenhagen, Denmark, dedicated to clinical development and registration of oncology products. In collaboration with Spectrum Pharmaceuticals, Inc., Topotarget focuses on the development of its lead drug candidate, belinostat, which has shown positive results in the treatment of hematological malignancies and solid tumors, obtained by both mono- and combination therapy. For more information, please refer to www.topotarget.com.
Topotarget Safe Harbor Statement
This announcement may contain forward-looking statements, including statements about Topotarget A/S’ expectations to the progression of Topotarget A/S’ clinical pipeline and with respect to cash burn guidance. Such statements are subject to risks and uncertainties of which many are outside the control of Topotarget A/S, and which could cause actual results to differ materially from those described. Topotarget A/S disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, unless required by Danish law.
